Fingerprint Dive into the research topics where Hematology and Oncology is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.

Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Survival Medicine & Life Sciences
Cisplatin Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1975 2021

Survival Rate
Prospective Studies
Breast Neoplasms
Organized Financing
Electronic Health Records
Molecular Imaging
Stem Cells
Acute Myeloid Leukemia

Research Output 1976 2019

1 Citation (Scopus)

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol

Levy, B., Paz-Ares, L., Bennouna, J., Felip, E., Abreu, D. R., Isla, D., Barlesi, F., Molinier, O., Madelaine, J., Audigier-Valette, C., Kim, S. W., Kim, H. R., Ozguroglu, M., Erman, M., Badin, F. B., Mekhail, T. M., Scheff, R., Chisamore, M. J., Sadrolhefazi, B. & Riess, J., Jan 1 2019, In : Clinical lung cancer.

Research output: Contribution to journalArticle

Open Access
Squamous Cell Carcinoma
Epidermal Growth Factor Receptor
3 Citations (Scopus)

Analysis of cell-free DNA from 32,989 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations

Rich, T. A., Reckamp, K. L., Chae, Y. K., Doebele, R. C., Iams, W. T., Oh, M., Raymond, V. M., Lanman, R. B., Riess, J. W., Stinchcombe, T. E., Subbiah, V., Trevarthen, D. R., Fairclough, S., Yen, J. & Gautschi, O., Jan 1 2019, In : Clinical Cancer Research. 25, 19, p. 5832-5842 11 p.

Research output: Contribution to journalArticle

Open Access
Gene Fusion
Circulating Neoplastic Cells
Phase II Clinical Trials
1 Citation (Scopus)

An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer

Morgensztern, D., Karaseva, N., Felip, E., Delgado, I., Burdaeva, O., Dómine, M., Lara, P. N., Paik, P. K., Lassen, U., Orlov, S., Trigo, J., Shomova, M., Baker-Neblett, K., Vasquez, J., Wang, X., Yan, L., Mitrica, I., DeYoung, M. P. & Garrido, P., Oct 1 2019, In : Lung Cancer. 136, p. 74-79 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Maximum Tolerated Dose